YOLT203 / YolTech Therap - LARVOL DELTA

Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1) (clinicaltrials.gov) - P2 | N=36 | Recruiting | Sponsor: YolTech Therapeutics Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Nephrology

Study of YOLT-203 in Children and Adults With Primary Hyperoxaluria Type 1 (PH1) (clinicaltrials.gov) - P2 | N=36 | Not yet recruiting | Sponsor: YolTech Therapeutics Co., Ltd

New P2 trial • Nephrology

Phase I Exploratory Study of YOLT-203 in Patients With Primary Hyperoxaluria Type 1 (PH1) (clinicaltrials.gov) - P1 | N=9 | Recruiting | Sponsor: YolTech Therapeutics Co., Ltd

New P1 trial • Nephrology

Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1) (clinicaltrials.gov) - P1 | N=2 | Active, not recruiting | Sponsor: Guangzhou Women and Children's Medical Center

New P1 trial • Nephrology

Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1) (clinicaltrials.gov) - P1 | N=21 | Recruiting | Sponsor: RenJi Hospital | Trial completion date: Jan 2026 ➔ Dec 2026 | Trial primary completion date: Jan 2026 ➔ Dec 2026

Trial completion date • Trial primary completion date • Nephrology

Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1) (clinicaltrials.gov) - P1 | N=7 | Recruiting | Sponsor: RenJi Hospital | Trial primary completion date: Oct 2025 ➔ Jan 2026

Trial primary completion date • Nephrology

Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1) (clinicaltrials.gov) - P1 | N=7 | Not yet recruiting | Sponsor: RenJi Hospital

New P1 trial • Nephrology

Clinical Exploration Study of YOLT-203 in the Treatment of Type 1 Primary Hyperoxaluria (PH1) (clinicaltrials.gov) - P1 | N=7 | Recruiting | Sponsor: RenJi Hospital | Not yet recruiting ➔ Recruiting

Enrollment open • Nephrology